Immunotherapy combinations for colorectal cancer with liver tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests combinations of immunotherapy drugs for people with colorectal cancer that has spread to the liver and is scheduled for surgery. The goal is to see if these treatments are safe and effective before and after the operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread to your liver.
- You are planning to have surgery to remove the liver tumors.
- Your tumor is not a type called MSI-H or dMMR.
- You have not had certain immunotherapies (like Keytruda, Opdivo, or Yervoy) before.
- You are willing to let researchers study your tumor tissue after surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two immunotherapy drugs, botensilimab and balstilimab, for people with colorectal cancer who have had surgery and chemotherapy but still have detectable cancer DNA in their blood. The goal is to see if these drugs can help clear the remaining cancer cells.
This trial tests a new way to deliver immunotherapy directly into the liver for people with colorectal cancer that has spread only to the liver. The goal is to see if this approach can shrink tumors before surgery, and it may be an option if you've already had standard chemotherapy.
This study tests a combination of three drugs for patients with colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor), growth factors, and chemotherapy (CapeOX) for people whose colorectal cancer has spread only to the liver. The goal is to see if this combination shrinks the tumors enough to allow surgery to remove them completely.
This trial combines targeted radiation (SBRT) with an immunotherapy drug (PD-1 inhibitor) to treat colorectal cancer that has spread to the liver and can't be removed by surgery. It aims to help shrink or control tumors in patients whose cancer has a normal DNA repair system (pMMR/MSS).
This trial tests a combination of two immunotherapy drugs (sintilimab and bevacizumab) plus chemotherapy for people with a specific type of colorectal cancer that hasn't spread to the liver. It may be an option if your cancer is mismatch repair stable (MSS or pMMR) and has progressed after initial treatment.
Hear when a new Liver Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.